Enzyme replacement therapy in the home setting for mucopolysaccharidosis vi: A survey of patient characteristics and physicians' early findings in the united states

Journal of Infusion Nursing

Volumn 32, Issue 1, 2009, Pages 45-52

  Tifft, Cynthia ^a   Proud, Virginia ^b   Levy, Paul ^c   DeMarco, Kristin ^d   Nicely, Helen ^d   Turbeville, Sean ^d  

^a CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^b Eastern Virginia Medical School   (Canada)

^c CHILDREN S HOSPITAL AT MONTEFIORE   (United States)

^d BIOMARIN PHARMACEUTICAL INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GALSULFASE; N ACETYLGALACTOSAMINE 4 SULFATASE; RECOMBINANT PROTEIN;

ADOLESCENT; ADULT; AORTA STENOSIS; ARTICLE; CASE REPORT; CHILD; DYSOSTOSIS; ENZYME REPLACEMENT; HEALTH SURVEY; HEPATOSPLENOMEGALY; HERNIA; HOME CARE; HUMAN; HYDROCEPHALUS; INFUSION; MAROTEAUX LAMY SYNDROME; PRIORITY JOURNAL; SCHOOL CHILD; INFORMATION PROCESSING; INTRAVENOUS DRUG ADMINISTRATION; PHYSICIAN; UNITED STATES;

DATA COLLECTION; HOME INFUSION THERAPY; HUMANS; INFUSIONS, INTRAVENOUS; MUCOPOLYSACCHARIDOSIS VI; N-ACETYLGALACTOSAMINE-4-SULFATASE; PHYSICIANS; RECOMBINANT PROTEINS; UNITED STATES;

EID: 61749099059     PISSN: 15331458     EISSN: None     Source Type: Journal    
DOI: 10.1097/NAN.0b013e31819228ee     Document Type: Article

References (10)

1. Litjens T, Hopwood JJ. Mucopolysaccharidosis type VI: structural and clinical implications of mutations in N-acetylgalactosamine-4-sulfatase. Hum Mutat. 2001;18:4-282.
2. Neufeld EF, Muenzer J. The mucopolysaccharidoses. In: Scriver CR, Beaudet AL, Valled D, eds. The Metabolic and Molecular Bases of Inherited Disease. 8th ed. New York: McGraw-Hill Inc; 2001:3421-3452.
3. Naglazyme® [package insert]. Novato, CA: BioMarin Pharmaceutical Inc; 2005.
4. Harmatz P, Whitley C, Waber L, et al. Enzyme replacement therapy in mucopolysaccharidosis VI (Maroteaux-Lamy syndrome). J Pediatr. 2004;144:574-580.
5. Harmatz P, Ketteridge D, Giugliani R, et al. Direct comparison of measures of endurance, mobility, and joint function during enzyme-replacement therapy of mucopolysaccharidosis VI (Maroteaux-Lamy syndrome): results after 48 weeks in a phase 2 open-label clinical study of recombinant human N-acetlygalactosamine-4-sulfatase. Pediatrics. 2005;115(6):e681-e689.
6. Harmatz P, Giugliani R, Schwartz I, et al. Enzyme replacement therapy for mucopolysaccharidosis VI: a phase 3, randomized, double-blind, placebo-controlled multinational study of recombinant human N- acetylgalactosamine-4-sulfatase (rhASB) and follow-on open-label extension study. J Pediatr. 2006;148:533- 539.
7. Cox-Brinkman J, Timmermans R, Wijburg F, et al. Home treatment with enzyme replacement therapy for mucopolysaccharidosis type 1 is feasible and safe. J Inherit Metab Dis. 2007;30:6-984.
8. Giugliani R, Harmatz P, Wraith J. Management guidelines for mucopolysaccharidosis VI. Pediatrics. 2007;120:2-405.
9. Cesario D, Clark J, Maisel A. Beneficial effects of intermittent home administration of the inotrope/vasodilator milrinone in patients with end-stage congestive heart failure: a preliminary study. Am Heart J. 1998;135:1-121.
10. Wardley A, Davidson N, Barrett-Lee P, et al. Zolendronic acid significantly improves pain scores and quality of life in breast cancer patients with bone metastases: a randomised crossover study of community versus hospital bisphosphonate administration. Br J Cancer. 2005;92:1869-1876.